hematopoiet
stem
cell
transplant
hsct
remain
one
potenti
cur
therapi
patient
benign
malign
blood
disord
concept
hsct
first
recogn
anim
model
mean
marrow
recoveri
follow
lethal
dose
total
bodi
irradi
concept
report
thoma
et
al
human
patient
leukemia
today
hsct
broad
indic
expand
includ
benign
malign
condit
hsct
categor
two
main
type
autolog
allogen
summari
key
differ
type
transplant
provid
fig
autolog
hsct
involv
use
patient
stem
cell
rescu
bone
marrow
follow
administr
highdos
myeloabl
chemotherapi
aim
type
transplant
erad
residu
cancer
cell
demonstr
intermedi
resist
standard
dose
chemotherapi
cytotox
main
benefit
type
transplant
immun
attack
cancer
cell
relapsedaggress
lymphoma
multipl
myeloma
remain
primari
indic
autolog
hsct
howev
use
type
transplant
also
extend
autoimmun
diseas
comprehens
list
potenti
indic
autolog
stem
cell
transplant
provid
tabl
allogen
hsct
involv
infus
stem
cell
relat
unrel
donor
result
two
mechan
fight
cancer
mechan
diseas
erad
includ
cytotox
effect
chemotherapi
donor
immun
system
attack
residu
cancer
cell
graftversustumor
effect
addit
elimin
residu
cancer
cell
chemotherapi
administ
allogen
stem
cell
transplant
use
also
suppress
recipi
immun
system
prevent
reject
donor
cell
graft
patient
typic
receiv
addit
immunosuppress
therapi
calcineurin
inhibitor
ie
tacrolimu
sirolimu
mycophenol
mofetil
andor
drug
methotrex
antithymocyt
globulin
prevent
reject
graft
protect
normal
recipienthost
cell
attack
graft
known
graftversushost
diseas
gvhd
acut
leukemia
myelodysplast
syndrom
remain
common
indic
allogen
hsct
howev
advanc
chronic
leukemia
lymphoma
hemoglobinopathi
also
treat
type
transplant
comprehens
list
indic
allogen
hsct
provid
tabl
allogen
hsct
one
first
exampl
immunotherapi
oncolog
abil
use
donor
immun
system
mean
fight
cancer
addit
chang
hematopoiet
progenitor
cell
chang
recipi
donor
immun
system
occur
cellular
therapi
build
foundat
collect
infus
hematopoiet
cell
use
anticanc
therapi
therapeut
immunolog
effect
graft
first
describ
field
allogen
stem
cell
transplant
graftversusleukemia
effect
gvl
gvleffect
identifi
follow
observ
decreas
relaps
rate
leukemia
patient
develop
graftversushost
diseas
gvhd
allogen
stem
cell
transplant
support
increas
relaps
rate
seen
syngen
transplant
transplant
use
tcelldeplet
graft
gvl
effect
caus
mostli
donor
lymphocyt
prompt
use
donor
lymphocyt
infus
one
earlier
form
cellular
therapi
subsequ
modifi
genet
antigen
specif
ie
chimer
antigen
receptor
car
modifi
tcell
target
differ
type
leukemia
lymphoma
malign
regardless
type
transplant
patient
receiv
hsct
undergo
similar
process
center
around
day
stem
cell
infus
known
day
day
prior
transplant
design
minu
sign
thu
day
would
repres
day
prior
plan
infus
stem
cell
day
infus
stem
cell
design
plu
sign
day
would
indic
patient
day
post
infus
stem
cell
transplant
process
start
referr
consult
stem
cell
transplant
team
initi
process
insurancefinanci
clearanc
assess
comorbiditiesorgan
function
evalu
function
statu
patient
decis
type
transplant
indic
process
typic
take
month
occur
concomitantli
primari
salvag
therapi
manag
diseas
patient
clinic
suitabl
financi
approv
arrang
made
collect
stem
cell
either
via
apheresi
case
autolog
allogen
hsct
bone
marrow
harvest
select
case
allogen
stem
cell
transplant
actual
transplant
process
begin
patient
receiv
condit
chemotherapi
known
also
prepar
regimen
gener
pretranspl
condit
regimen
consist
combin
chemotherapi
drug
without
radiat
goal
immunosuppress
recipi
elimin
much
tumor
possibl
regimen
classifi
myeloabl
nonmyeloabl
reduc
intens
myeloabl
regimen
defin
abil
erad
recipi
bone
marrow
associ
profound
cytopenia
lack
autolog
hematopoiet
recoveri
nonmyeloabl
nma
regimen
typic
caus
minim
cytopenia
reli
primarili
gvl
effect
diseas
erad
reducedintens
protocol
intermedi
intens
group
regimen
middl
road
abl
nma
condit
prefer
prepar
regimen
depend
upon
combin
diseas
patientrel
factor
condit
regimen
typic
administ
day
day
day
rest
prior
stem
cell
infus
allow
clearanc
cytotox
chemotherapi
therebi
avoid
potenti
damag
infus
stem
cell
day
stem
cell
infus
patient
via
central
venou
cathet
case
allogen
stem
cell
transplant
patient
also
receiv
immunosuppress
therapi
typic
start
day
prior
infus
stem
cell
often
continu
month
posttranspl
patient
receiv
combin
antimicrobi
antifung
antivir
prophylact
therapi
pretranspl
process
end
infus
stem
cell
summar
fig
next
phase
transplant
commonli
known
recoveri
period
begin
infus
stem
cell
patient
undergo
autolog
hsct
period
typic
last
month
culmin
administr
vaccin
allogen
hsct
period
may
last
longer
depend
upon
whether
patient
develop
graftversushost
diseas
transplantrel
complic
discuss
later
chapter
autolog
allogen
hsct
recoveri
period
associ
approxim
week
myelosuppress
condit
chemotherapi
regimen
time
donor
cell
migrat
bone
marrow
begin
produc
new
blood
cell
patient
may
requir
transfus
blood
product
time
greatest
risk
bacteri
fungal
certain
viral
infect
due
low
neutrophil
count
potenti
mucos
damag
mucos
extent
immunosuppress
time
determin
intens
chemotherapi
regimen
immunosuppress
may
prolong
allogen
hsct
due
use
steroid
immunosuppress
medic
treatment
gvhd
posthsct
process
summar
fig
appropri
patient
select
autolog
hsct
gener
consid
welltoler
procedur
estim
transplantrel
mortal
trm
less
within
first
day
posttranspl
fact
common
caus
death
autolog
hsct
remain
diseas
relaps
account
death
use
myeloabl
chemotherapi
autolog
hsct
result
profound
pancytopenia
put
patient
risk
bacteri
fungal
viral
infect
patient
tend
greatest
risk
bacteri
infect
earli
posttranspl
period
prior
neutrophil
engraft
although
infect
like
viral
fungal
also
occur
time
period
estim
rate
admiss
icu
autolog
hsct
remain
low
one
studi
patient
show
rate
overal
mortal
patient
cohort
howev
increas
patient
admit
icu
common
reason
icu
admiss
system
inflammatori
responsesepsi
respiratori
failur
cardiovascular
failur
major
patient
underli
diagnosi
multipl
myeloma
al
amyloidosi
greatest
diseasespecif
icu
mortal
associ
al
amyloidosi
patient
studi
also
found
correl
mortal
sequenti
organ
failur
assess
sofa
score
acut
physiolog
chronic
health
evalu
apach
ii
score
first
h
icu
admiss
suggest
possibl
tool
assist
clinic
decisionmak
regard
continu
intens
care
deliv
h
icu
admiss
addit
infecti
complic
mani
patient
undergo
autolog
hsct
develop
gastrointestin
complic
prepar
chemotherapi
regimen
two
common
prepar
regimen
autolog
hsct
singleag
melphalan
primarili
use
plasma
cell
disord
combin
bcnucarmustin
etoposid
araccytarabin
melphalan
beam
primarili
use
lymphoma
regimen
consid
myeloabl
may
result
vari
degre
damag
gi
tract
mucosa
mucos
nauseavomit
diarrhea
alter
tast
period
anorexia
neutropenia
last
week
may
associ
neutropen
fever
bacteremia
requir
broad
antimicrobi
coverag
occasion
sepsi
need
icu
care
addit
older
patient
may
prone
cardiac
toxic
develop
atrial
fibril
especi
histori
atrial
fibril
renal
insuffici
volum
overload
howev
effect
tend
resolv
within
short
period
time
neutrophil
engraft
occur
late
effect
autolog
hsct
rel
uncommon
second
primari
malign
obstructiverestrict
lung
impair
viral
infect
report
late
complic
studi
lymphoma
survivor
found
cumul
incid
secondari
neoplasm
common
type
neoplasm
hematolog
malign
includ
myelodysplast
syndrom
md
myeloprolif
disord
mpn
acut
myelogen
leukemia
aml
studi
lymphoma
patient
japan
report
incid
md
aml
longterm
survivor
autolog
hsct
howev
increas
concern
patient
multipl
myeloma
found
trial
mainten
therapi
autolog
hsct
incid
secondari
malign
receiv
mainten
versu
without
mainten
therapi
pulmonari
complic
autolog
hsct
seem
rare
stenehjem
et
al
report
incid
obstruct
restrict
lung
impair
respect
lymphoma
survivor
autolog
hsct
current
smoke
cumul
doxorubicin
dose
risk
factor
obstruct
diseas
chest
radiat
greater
gy
seem
increas
risk
restrict
lung
diseas
pulmonari
complic
lastli
patient
receiv
autolog
hsct
remain
risk
viral
atyp
infect
ie
varicellazost
viru
pneumocysti
jirovecii
sever
month
postengraft
await
recoveri
lymphocyt
popul
usual
reach
safer
level
day
posttranspl
reason
mani
patient
remain
prophylact
medic
like
acyclovir
valacyclovir
bactrim
mepron
pentamidin
month
transplant
patient
also
recommend
undergo
repeat
vaccin
measl
mump
rubella
tetanu
diphtheria
haemophilu
influenza
polio
influenza
typic
begin
month
transplant
preengraft
period
patient
start
experi
side
effect
condit
chemotherapi
regimen
includ
primarili
nausea
vomit
mucos
diarrhea
fever
infect
also
common
time
gramposit
bacteria
gramneg
bacteria
herp
simplex
viru
respiratori
virus
enter
virus
fungal
infect
especi
candida
aspergillu
speci
preval
earli
postengraft
period
defin
time
engraft
day
time
risk
bacteri
infect
tend
gradual
declin
howev
patient
tend
develop
increas
risk
viral
infect
immunemedi
effect
donor
cell
noninfecti
pulmonari
gastrointestin
liver
toxic
patient
also
continu
signific
anemia
thrombocytopenia
earli
postengraft
period
tend
persist
roughli
day
posttranspl
immunosuppress
medic
often
continu
month
posttranspl
may
continu
longer
patient
develop
graftversushost
diseas
immunosuppress
earli
postengraft
time
result
prolong
period
increas
risk
infect
await
reconstitut
matur
function
lymphocyt
popul
reason
allogen
hsct
patient
tend
increas
risk
atyp
viral
fungal
infect
also
anoth
peak
risk
aspergillu
infect
along
potenti
pneumocysti
infect
tabl
list
common
organ
manifest
viral
infect
seen
allogen
hsct
patient
earli
noninfecti
complic
allogen
hsct
includ
fluid
overload
acut
gvhd
liver
complic
pulmonari
complic
idiopath
pneumonia
syndrom
diffus
alveolar
hemorrhag
hemorrhag
cystiti
fluid
overload
common
complic
allogen
hsct
retrospect
singl
institut
studi
patient
undergo
allogen
hsct
rondon
et
al
identifi
syndrom
fluid
overload
occur
earli
posttranspl
absenc
known
transplant
complic
character
degre
weight
gain
edema
necessit
fluid
remov
without
organ
toxic
studi
propos
follow
grade
system
fluid
overload
grade
weight
gain
baselin
asymptomat
mild
edema
possibl
requir
diuret
therapi
decreas
intraven
fluid
replac
grade
symptomat
fluid
retent
without
weight
gain
baselin
requir
ongo
diuret
therapi
grade
weight
gain
baselin
respond
diuret
therapi
possibl
renal
pulmonari
cardiac
dysfunct
requir
treatment
grade
progress
dysfunct
organ
system
requir
intens
care
studi
includ
two
cohort
first
studi
cohort
patient
undergo
haploident
hsct
melphalanfludarabinebas
condit
regimen
fluid
overload
occur
cohort
multivari
analysi
show
grade
hr
ci
p
serum
creatinin
level
mgdl
transplant
admiss
hr
ci
p
significantli
associ
day
nonrelaps
mortal
valid
cohort
amlmd
patient
undergo
transplant
hlamatch
relat
unrel
donor
follow
busulfanfludarabinebas
condit
regimen
acut
gvhd
remain
signific
caus
earli
transplantrel
mortal
acut
set
gvhd
felt
primarili
tcelldriven
process
initi
tissu
damag
condit
regimen
follow
donor
tcell
activ
associ
inflammatori
respons
risk
factor
acut
gvhd
includ
limit
increas
donorrecipi
hla
disparitymismatch
increas
donor
age
multipar
femal
donor
use
peripher
blood
stem
cell
myeloabl
condit
acut
gvhd
affect
multipl
organ
common
skin
gastrointestin
tract
liver
skin
commonli
affect
organ
acut
gvhd
typic
consist
maculopapular
rash
may
prurit
even
pain
gastrointestin
gi
tract
involv
typic
categor
upper
lower
base
upon
clinic
symptom
may
support
tissu
diagnosi
biopsi
upper
gi
gvhd
typic
present
nausea
anorexia
wherea
lower
gi
tract
involv
typic
present
profus
wateri
diarrhea
abdomin
cramp
liver
involv
less
common
typic
present
cholestat
pictur
prophylaxi
acut
gvhd
aim
decreas
expans
activ
donor
tcell
accomplish
manipul
graft
deplet
tcell
popul
pharmacolog
agent
eg
methotrex
cyclosporin
calcineurin
inhibitor
tacrolimu
sirolimu
frontlin
treatment
acut
gvhd
involv
use
high
dose
corticosteroid
may
suppress
patient
immun
system
therebi
increas
risk
infect
liver
diseas
hsct
multipl
potenti
etiolog
mani
problem
present
within
first
day
transplant
reactiv
viral
hepat
fatti
liver
iron
overload
acut
drug
toxic
like
common
caus
abnorm
liver
function
test
transplant
acut
onset
ascit
weight
gain
fluid
retent
andor
rise
bilirubin
prompt
concern
venoocclus
diseas
vod
sinusoid
obstruct
syndrom
so
vodso
thought
result
preexist
damag
hepat
venou
endotheli
cell
lead
procoagul
state
lead
deposit
fibrinogen
factor
viii
within
venular
wall
liver
sinusoid
lead
progress
venular
occlus
follow
deposit
collagen
sinusoid
sclerosi
venular
wall
fibrosi
venular
lumen
occlus
termin
hepat
venul
intercal
vein
preexist
liver
diseas
combin
exposur
highdos
alkyl
agent
seem
pose
highest
risk
develop
vodso
commonli
use
criteria
diagnosi
condit
summar
tabl
doppler
ultrasound
liver
liver
biopsi
may
necessari
differenti
vodso
acut
gvhd
liver
one
promis
therapi
vodso
defibrotid
polydeoxyribonucleotid
adenosin
receptor
agonist
shown
affect
endotheli
cell
function
releas
prostanoid
increas
tissu
plasminogen
activ
tpa
decreas
level
plasminogen
activ
inhibitor
inhibit
thrombininduc
platelet
aggreg
inhibit
leukocyt
adhes
endotheli
cell
studi
defibrotid
shown
complet
respons
rate
includ
treatment
patient
sever
vodso
idiopath
pneumonia
syndrom
condit
character
widespread
alveolar
injuri
occur
absenc
activ
lower
respiratori
infect
cardiac
caus
encompass
spectrum
pulmonari
disord
seen
tabl
estim
incid
within
first
day
hsct
typic
onset
around
week
posttranspl
estim
day
mortal
treatment
often
empir
broadspectrum
antimicrobi
highdos
corticosteroid
bronchoscopi
bronchoalveolar
lavag
bal
recommend
guid
therapi
patient
adequ
platelet
count
transbronchi
biopsi
andor
open
lung
biopsi
may
requir
accur
diagnosi
anoth
potenti
respiratori
complic
transplant
develop
diffus
alveolar
hemorrhag
dah
rare
condit
high
mortal
rate
diagnosi
suggest
find
patchi
bilater
ground
glass
consolid
opac
imag
confirm
bronchoscopi
sampl
show
progress
hemorrhag
return
sequenti
lavag
subseg
lung
sampl
may
also
show
hemosiderinladen
macrophag
cytolog
treatment
mostli
support
care
broadspectrum
antibiot
case
suspect
secondari
infect
glucocorticoid
steroid
treatment
underli
inflamm
ie
capillar
potenti
acut
gvhd
associ
case
use
steroid
nongvhd
case
remain
somewhat
controversi
sinc
mix
data
regard
efficaci
also
grow
evid
potenti
use
recombin
factor
vii
treatment
dah
hemorrhag
cystiti
complic
occur
two
differ
time
point
hsct
patient
preengraft
period
commonli
associ
preparativecondit
regimen
treatment
given
condit
regimen
associ
hemorrhag
cystiti
includ
highdos
cyclophosphamid
ifosfamid
busulfan
total
bodi
irradi
howev
hemorrhag
cystiti
occur
postengraft
period
primarili
relat
bk
polyomaviru
infect
typic
occur
within
first
day
posttranspl
like
altern
donor
transplant
eg
unrel
donor
haploident
cord
blood
transplant
haploident
transplant
incid
grade
hemorrhag
cystiti
approxim
associ
obstruct
renal
insuffici
use
alemtuzumab
part
condit
regimen
also
associ
increas
risk
bk
virusassoci
hemorrhag
cystiti
reactiv
bk
viru
also
associ
delay
immunolog
reconstitut
treatment
includ
predominantli
drug
cytotox
tcell
lymphocyt
ctl
cidofovir
predomin
pharmacolog
agent
use
treat
bk
viru
infect
estim
overal
respons
rate
includ
complet
respons
patient
fail
respond
pharmacolog
therapi
contraind
therapi
use
ctl
potenti
option
occasion
patient
requir
percutan
nephrostomi
tube
placement
manag
ureter
stenosi
obstruct
late
postengraft
period
defin
anytim
beyond
day
diseas
progress
remain
common
caus
mortal
late
postengraft
period
account
estim
death
day
allogen
hsct
howev
patient
may
experi
longterm
qualiti
life
psychosoci
issu
includ
concern
sexual
fertil
financi
toxic
integr
back
societi
patient
also
remain
risk
infect
encapsul
organ
varicellazost
viru
await
complet
immun
reconstitut
may
take
year
allogen
hsct
patient
much
like
earli
postengraft
period
patient
requir
prolong
immunosuppress
corticosteroid
time
period
remain
increas
risk
varieti
viral
fungal
infect
requir
ongo
prophylaxi
anoth
late
effect
hsct
risk
secondari
cancer
myeloid
malign
ie
secondari
myelodysplast
syndrom
therapyrel
acut
myelogen
leukemia
common
autolog
hsct
report
incid
solid
cancer
patient
recipi
autolog
allogen
hsct
incid
seem
plateau
respons
late
death
hsct
risk
factor
includ
advanc
age
use
total
bodi
irradi
develop
chronic
gvhd
total
bodi
irradi
seem
strong
associ
develop
adenocarcinoma
wherea
chronic
gvhd
seem
associ
squamou
cell
carcinoma
skin
anoth
uniqu
malign
seen
ebv
seroposit
patient
allogen
hsct
tcelldeplet
graft
intens
immunosuppress
posttranspl
lymphoprolif
diseas
ptld
lastli
develop
chronic
gvhd
major
caus
morbid
reduc
qualiti
life
longterm
survivor
hsct
chronic
gvhd
treatment
sever
immunosuppress
condit
could
associ
variou
infecti
complic
relat
tcell
dysfunct
like
fungal
viral
infect
occasion
may
need
icu
care
unlik
acut
gvhd
chronic
gvhd
tend
gradual
onset
symptom
start
month
transplant
may
evolv
organ
fibrosi
involv
primarili
skinfascia
classic
case
chronic
gvhd
tend
occur
day
transplant
patient
develop
symptom
earlier
progress
evolut
acut
gvhd
known
overlap
syndrom
wherebi
patient
exhibit
sign
symptom
acut
chronic
gvhd
approxim
case
chronic
gvhd
preced
acut
gvhd
increas
risk
patient
receiv
peripher
blood
stem
cell
unrel
donor
treatment
includ
system
therapi
aim
control
underli
destruct
immunolog
process
steroid
ruxolitinib
photopheresi
also
provid
aggress
support
care
address
symptom
pain
jointfascia
tight
chronic
dri
mouth
dri
eye
patient
also
requir
ongo
surveil
skin
cancer
best
accomplish
experienc
transplant
center
multidisciplinari
team
includ
transplant
physician
physic
therapist
occup
therapist
dermatologist
ophthalmologist
avail
resourc
stem
cell
transplant
associ
complic
may
requir
admiss
intens
care
unit
icu
estim
rate
icu
admiss
autolog
hsct
approxim
rang
allogen
hsct
commonli
report
reason
icu
admiss
respiratori
failur
sepsi
infect
although
icu
admiss
stem
cell
transplant
patient
especi
allogen
graft
associ
poor
prognosi
overal
surviv
hsct
patient
requir
intens
care
unit
icu
admiss
improv
year
fact
singl
institut
studi
patient
hematolog
malign
admit
icu
show
differ
surviv
patient
receiv
transplant
patient
receiv
transplant
furthermor
singl
center
retrospect
studi
allogen
hsct
recipi
admit
icu
show
longterm
surviv
rate
year
year
respect
similar
patient
never
requir
intens
care
van
vliet
et
al
also
show
admiss
icu
neg
impact
longterm
healthrel
qualiti
life
patient
treat
hematolog
malign
fortyf
percent
patient
studi
recipi
hsct
howev
one
ongo
struggl
hsct
patient
icu
abil
predict
prognosi
optim
time
endoflif
discuss
patient
caregiv
commun
icu
transplant
team
key
factor
avoid
conflict
time
admiss
icu
goal
care
seem
particularli
issu
patient
undergo
allogen
hsct
cur
intent
studi
tradit
organ
function
index
ie
apach
ii
apach
iii
sofa
seem
provid
conflict
result
abil
predict
icu
outcom
hsct
popul
afessa
et
al
found
apach
iii
score
moder
discrimin
good
calibr
predict
hospit
mortal
apach
ii
score
prognost
valu
gilli
et
al
conclud
apach
ii
score
underestim
mortal
use
sofa
score
correl
hospit
mortal
specif
patient
sofa
score
surviv
studi
two
studi
also
show
correl
higher
sofa
score
increas
hospit
mortal
studi
also
suggest
need
mechan
ventil
associ
shorter
surviv
furthermor
combin
liver
failur
renal
failur
mechan
ventil
hsct
patient
seem
univers
fatal
addit
commun
among
provid
also
imper
transplant
team
address
advanc
care
plan
acp
patient
prior
hsct
ganti
et
al
show
studi
patient
undergo
hsct
includ
allogen
autolog
acp
associ
decreas
risk
posthsct
mortal
estim
probabl
surviv
without
acp
acp
hr
risk
death
ci
p
group
conclud
patient
least
like
plan
poor
outcom
like
face
engag
acp
inconsist
hope
best
outcom
hsct
conclus
icu
care
hematopoiet
stem
cell
transplant
patient
complex
due
sever
immunosuppress
state
patient
earli
posttranspl
period
complic
primarili
relat
infect
organ
failur
chemotherapi
even
though
concern
remain
need
icu
care
allogen
hematopoiet
transplant
recipi
sever
studi
shown
encourag
result
like
relat
overal
lower
intens
condit
regimen
better
prevent
infecti
complic
expand
avail
treatment
option
better
recognit
potenti
complic
occur
patient
